AFP | New cancer drugs help drive Roche in first half PMLiVE MabThera/ Rituxan (rituximab) for blood cancers and arthritis climbed 3 per cent to CHF 3.40bn and breast cancer stalwart Herceptin (trastuzumab) rose 5 per cent to 3.08bn Swiss francs, both benefitting from strong uptake in emerging markets and ... Strong 1st-half at Roche driven by cancer drug |
